140
Participants
Start Date
July 1, 2020
Primary Completion Date
December 31, 2024
Study Completion Date
June 30, 2025
Masitinib
Masitinib 6 mg/kg/day
Placebo
Matching placebo
Best Supportive Care
Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, proton pump inhibitors (PPI), sodium cromoglycate, antidepressants, leukotriene antagonists and corticosteroids.
RECRUITING
Centre Hospitalier Universitaire d'Amiens, Amiens
RECRUITING
Hospital Jean-Minjoz, Besançon
RECRUITING
Grenoble University Hospital, Grenoble
RECRUITING
Hospital Claude Huriez, Lille
RECRUITING
Marseille University Hospital Timone, Marseille
RECRUITING
Centre de référence de Mastocytose (CEREMAST), Paris
RECRUITING
Poitiers University Hospital, Poitiers
RECRUITING
Centre Hospitalier Universitaire, Toulouse
NOT_YET_RECRUITING
University Hospital Charité, Berlin
RECRUITING
Erasmus University Medical Center, Rotterdam
RECRUITING
Medical University of Gdańsk, Gdansk
RECRUITING
The University Hospital in Krakow (Szpital Uniwersytecki w Krakowie), Krakow
RECRUITING
University Hospital in Bucharest (Spitalul Universitar de Urgență București), Bucharest
RECRUITING
Almazov National Medical Research Centre, Saint Petersburg
RECRUITING
Dnipropetrovsk Clinical Association of Emergency Medical Care of Dnipropetrovsk Regional, Dnipro
RECRUITING
Private Enterprise Private Manufacturing Company Acinus, Poltava
RECRUITING
Guy's and St Thomas' NHS Foundation Trust, London
Lead Sponsor
AB Science
INDUSTRY